'Brentuximab vedotin' diaporamas de présentation

ASCO REVIEW 2011 T Martin, MD ASCO, Lugano, IMF-Paris Highlights May - June, 2011

739 views • 62 slides

Hot Topics in Lymphoma Supportive Care

Hot Topics in Lymphoma Supportive Care. Program Goal. Program Overview. Lenalidomide. Lenalidomide Toxicities. Lenalidomide-Associated Tumor Flare Reaction. Management of Tumor Flare Reaction. Bendamustine. Bendamustine-Associated Toxicities. Skin Reactions. Managing Skin Reactions.

693 views • 50 slides

Morton Coleman, M.D. Director, Center for Lymphoma and Myeloma Weill Cornell Medical Center

Morton Coleman, M.D. Director, Center for Lymphoma and Myeloma Weill Cornell Medical Center New York Presbyterian Hospital New York, New York. Hodgkin Lymphoma: Latest Concepts. THE MAIN INTENT: LESS TOXICITY.

666 views • 49 slides

Morton Coleman, M.D. Director, Center for Lymphoma and Myeloma Weill Cornell Medical Center

Morton Coleman, M.D. Director, Center for Lymphoma and Myeloma Weill Cornell Medical Center New York Presbyterian Hospital New York, New York. Hodgkin Lymphoma: Latest Concepts. THE MAIN INTENT: LESS TOXICITY.

494 views • 49 slides

Brentuximab Vedotin. How and When Should it be Used in B and T cell Lymphomas

Lymphoma and Myeloma 2014 International Congress on Hematologic Malignancies New York. Brentuximab Vedotin. How and When Should it be Used in B and T cell Lymphomas. Ranjana Advani MD Professor of Medicine Saul Rosenberg Professor of Lymphoma Stanford University. Disclosures.

940 views • 48 slides

Advances in Lymphoma

Advances in Lymphoma. Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Ibrutinib Monotherapy. GS-9973 and Idelasib in Patients With R/R CLL. ABT-199 in Patients With R/R CLL/SLL. Hodgkin Lymphoma. ABVD With and Without Bleomycin and/or Dacarbazine.

667 views • 42 slides

Future directions: Can we improve outcomes in relapsed/refractory DLBCL or aggressive NHL?

370 views • 25 slides

Locatelli F et al. Proc ASH 2013;Abstract 4378.

Phase 1/2 Study of Brentuximab Vedotin in Pediatric Patients with Relapsed or Refractory (R/R) Hodgkin Lymphoma (HL) or Systemic Anaplastic Large-Cell Lymphoma (sALCL): Preliminary Phase 2 Data for Brentuximab Vedotin 1.8 mg/kg i n t he HL Study Arm. Locatelli F et al.

279 views • 13 slides

Chen R et al. Proc ASH 2010 ; Abstract 283.

Results of a Pivotal Phase 2 Study of Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Hodgkin Lymphoma. Chen R et al. Proc ASH 2010 ; Abstract 283. Brentuximab Vedotin Mechanism of Action. Brentuximab vedotin (SGN-35) antibody-drug conjugate (ADC)

403 views • 9 slides

Duvic M et al. Proc ASH 2013;Abstract 367.

Phase II Trial of Brentuximab Vedotin for CD30+ Cutaneous T -Cell Lymphomas and Lymphoproliferative Disorders. Duvic M et al. Proc ASH 2013;Abstract 367. Background.

275 views • 8 slides

Shustov AR et al. Proc ASH 2010 ; Abstract 961.

Complete Remissions with Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma. Shustov AR et al. Proc ASH 2010 ; Abstract 961. Background.

183 views • 8 slides